A Phase Ib Study to Evaluate Efficacy, Safety and Tolerability of KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

Peking University1 site in 1 country48 target enrollmentSeptember 26, 2019

ConditionsHER2 Positive Solid Tumor

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: HER2 Positive Solid Tumor
Sponsor: Peking University
Enrollment: 48
Locations: 1
Primary Endpoint: Duration of response (DOR)
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a phase Ib, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN026 combined with KN046 in subjects with advanced HER2 positive solid tumors.

Detailed Description

The study is composed of 2 stages. Stage 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 consists of 4 tumor type expansion cohorts for expanding the information on clinical safety, clinical pharmacokinetics and antitumor activity in HER2 positive patients.

Registry

clinicaltrials.gov

Start Date

September 26, 2019

End Date

December 1, 2023

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Peking University

Responsible Party

Principal Investigator

Shen Lin

MD,Professor,Chief of Department of GI Oncology,Peking University Cancer Hospital

Peking University

Eligibility Criteria

Inclusion Criteria

•Signed inform consent form (ICF)
•Age ≥ 18 years and ≤ 75 years, male or female
•Histologically or cytologically documented advanced HER2 positive solid tumor
•Received at least one prior standard therapy
•At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors（RECISIT） v 1.1
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
•Adequate organ function
•LVEF≥ 50% (ECHO)
•Female patients and males with partners of childbearing potential should be using highly effective contraceptive measures (failure rate of less than 1% per year). Contraception should be continued for a period of 24 weeks after dosing has been completed.
•Ability to comply with treatment, procedures and pharmacokinetics (PK) sample collection and the required study follow-up procedures

Exclusion Criteria

•Accepted any other anti-tumor drug therapies within 4 weeks before fist dose
•Accepted radiotherapy within 4 weeks before enrollment
•An anthracyclines antibiotic treatment was received exceeding 320 mg/m² or other equivalent dose antharcyclines
•Subjects are eligible with clinically controlled and stable neurologic function \>= 4 weeks, which is no evidence of CNS disease progression; Subjects with spinal cord compression and cancerous meningitis are not eligible
•Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement doses, equivalent to \< 10 mg prednisone daily, inhaled steroids and topical use of steroids)
•Vaccination within 28 days of the first administration of trial treatment, except for administration of inactivated vaccines (e.g., inactivated influenza vaccines)
•Pregnant or nursing females；or intend pregnancy within this study period or within 6 monthes after the end of this study
•Severe chronic and active infection, need to system antibiosis/antiviral treatment
•Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management
•Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage